AKT1 and cancer: Consistently, one study shows that a small molecule (compound SZL-P1-41) that binds to Skp2 and prevents its binding with Skp1 disrupts Skp2 E3-ligase activity toward Akt, leading to the suppression of cancer progression in mouse models [146].